Edwards Lifesciences (NYSE:EW) Rating Increased to Positive at OTR Global

Edwards Lifesciences (NYSE:EWGet Free Report) was upgraded by research analysts at OTR Global from a “mixed” rating to a “positive” rating in a research report issued on Tuesday, Benzinga reports.

EW has been the subject of several other research reports. Evercore ISI lowered shares of Edwards Lifesciences from an “outperform” rating to an “in-line” rating and lowered their price objective for the company from $80.00 to $77.00 in a research note on Thursday, January 4th. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. Citigroup lowered Edwards Lifesciences from a “buy” rating to a “neutral” rating in a report on Monday, December 11th. Wolfe Research downgraded Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $57.00 price target on the stock. in a report on Tuesday, November 28th. Finally, Oppenheimer lifted their price objective on Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 18th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $88.50.

Get Our Latest Analysis on EW

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $95.15 on Tuesday. Edwards Lifesciences has a one year low of $60.57 and a one year high of $95.35. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. The firm’s 50 day moving average price is $85.48 and its 200-day moving average price is $75.86. The firm has a market cap of $57.21 billion, a P/E ratio of 41.37, a P/E/G ratio of 4.62 and a beta of 1.05.

Edwards Lifesciences (NYSE:EWGet Free Report) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, hitting analysts’ consensus estimates of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The company had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same period in the prior year, the firm earned $0.64 earnings per share. The firm’s revenue was up 13.3% compared to the same quarter last year. As a group, equities research analysts predict that Edwards Lifesciences will post 2.76 EPS for the current year.

Insider Activity

In other Edwards Lifesciences news, Director Michael A. Mussallem sold 29,350 shares of the firm’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $72.98, for a total transaction of $2,141,963.00. Following the transaction, the director now owns 4,486 shares of the company’s stock, valued at $327,388.28. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $72.98, for a total value of $2,141,963.00. Following the completion of the sale, the director now directly owns 4,486 shares of the company’s stock, valued at $327,388.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Catherine M. Szyman sold 27,000 shares of Edwards Lifesciences stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the transaction, the vice president now directly owns 34,814 shares in the company, valued at $2,980,774.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 196,859 shares of company stock worth $16,445,296. Corporate insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds have recently made changes to their positions in the business. Sequoia Financial Advisors LLC grew its position in Edwards Lifesciences by 11.4% in the 1st quarter. Sequoia Financial Advisors LLC now owns 9,181 shares of the medical research company’s stock valued at $1,081,000 after buying an additional 941 shares during the last quarter. Zions Bancorporation N.A. boosted its holdings in shares of Edwards Lifesciences by 34.7% in the first quarter. Zions Bancorporation N.A. now owns 1,738 shares of the medical research company’s stock valued at $204,000 after acquiring an additional 448 shares in the last quarter. Covestor Ltd boosted its holdings in shares of Edwards Lifesciences by 18.2% in the first quarter. Covestor Ltd now owns 1,223 shares of the medical research company’s stock valued at $144,000 after acquiring an additional 188 shares in the last quarter. Mather Group LLC. increased its stake in shares of Edwards Lifesciences by 53.5% during the first quarter. Mather Group LLC. now owns 7,182 shares of the medical research company’s stock worth $846,000 after acquiring an additional 2,503 shares during the period. Finally, Mackenzie Financial Corp raised its holdings in Edwards Lifesciences by 3.1% during the first quarter. Mackenzie Financial Corp now owns 655,567 shares of the medical research company’s stock worth $77,173,000 after purchasing an additional 19,798 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

(Get Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Read More

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.